Imexpharm, a leader in Vietnam’s pharmaceutical industry, is entering a new growth phase with a focus on the production of invented drugs, leveraging advanced technology to meet stringent international standards.

Vietnam's pharmaceutical industry still faces many challenges and difficulties in the context of increasingly deep integration with the world, heard a seminar in Hanoi.

In its latest financial update, Imexpharm Corporation has reported strong growth in net revenue and significant strategic advancements, along with plans for a bonus share issuance to support future expansion.

After record profits and strong growth in 2023, the industry’s momentum faced limitations in 2024 due to rising raw material costs and increased market competition.

The Vietnamese pharmaceutical industry is seeing great advantages.

Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use.

Foreign enterprises are looking to collect shares of leading pharmaceutical companies in Việt Nam and become strategic shareholders.

Vietnam has set its sights on becoming a high-value pharmaceutical production hub within the region.

The UK – VN Free Trade Agreement (UKVFTA) were providing significant opportunities for Vietnam to attract foreign direct investment (FDI) into the pharmaceutical industry.

It is critical for pharmaceutical companies to improve competitiveness with a focus on research and development (R&D), production technology and digitalisation.

In the context of rising inflation, many retail businesses can continue to grow thanks to bolstering their activities in the pharmaceutical sector.

The Ministry of Health (MoH) will propose to the Government to issue policies aimed at encouraging domestic pharmaceutical enterprises to produce rare medicines in order to ensure domestic supply.